G, Y., K, K., R, K., T, M., F, P., SW, P., . . . G, K. (2025). Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: The ATLAS-OLE study. Blood, 145(25), 2966. https://doi.org/10.1182/blood.2024027008
Chicago Style (17th ed.) CitationG, Young, et al. "Safety and Efficacy of a Fitusiran Antithrombin-based Dose Regimen in People with Hemophilia A or B: The ATLAS-OLE Study." Blood 145, no. 25 (2025): 2966. https://doi.org/10.1182/blood.2024027008.
MLA (9th ed.) CitationG, Young, et al. "Safety and Efficacy of a Fitusiran Antithrombin-based Dose Regimen in People with Hemophilia A or B: The ATLAS-OLE Study." Blood, vol. 145, no. 25, 2025, p. 2966, https://doi.org/10.1182/blood.2024027008.
Warning: These citations may not always be 100% accurate.
